Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Total Non-Current Liabilities of $5.9 billion for Q1 2026, up 8.0% year-over-year from $5.4 billion in Q1 2025, and up 2.79% quarter-over-quarter from $5.7 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $5.9 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 8.0% year-over-year to $5.9 billion; the TTM figure through Mar 2026 stood at $5.9 billion (up 8.0% YoY), while the FY2025 annual figure was $5.7 billion, up 11.72% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $5.9 billion, up from $5.7 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $6.3 billion in Q3 2025, with the low at $3.2 billion in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $4.5 billion (2024), against an average of $4.7 billion.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities grew 6.71% in 2022, then soared 30.66% in 2024.
- Vertex Pharmaceuticals' Total Non-Current Liabilities stood at $3.6 billion in 2022, then advanced by 20.26% to $4.3 billion in 2023, then advanced by 19.59% to $5.1 billion in 2024, then gained by 11.72% to $5.7 billion in 2025, then advanced by 2.79% to $5.9 billion in 2026.
- Business Quant data shows VRTX's Total Non-Current Liabilities at $5.9 billion in Q1 2026, $5.7 billion in Q4 2025, and $6.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 378.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.92 Bn |
| Mar 31, 2026 | 5.87 Bn |
| Dec 31, 2025 | 5.71 Bn |
| Sep 30, 2025 | 6.31 Bn |
| Jun 30, 2025 | 5.67 Bn |
| Mar 31, 2025 | 5.43 Bn |
| Dec 31, 2024 | 5.11 Bn |
| Sep 30, 2024 | 5.68 Bn |
| Jun 30, 2024 | 4.48 Bn |
| Mar 31, 2024 | 4.52 Bn |
| Dec 31, 2023 | 4.27 Bn |
| Sep 30, 2023 | 4.34 Bn |
| Jun 30, 2023 | 4.12 Bn |
| Mar 31, 2023 | 3.82 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.56 Bn |
| Jun 30, 2022 | 3.52 Bn |
| Mar 31, 2022 | 3.23 Bn |
| Dec 31, 2021 | 3.03 Bn |
| Sep 30, 2021 | 2.98 Bn |